Omnihealth Practice

ONCOLOGY

Clinical challenges and considerations in managing HR+/HER2- advanced breast cancer in the post-CDK inhibitor setting

31 Dec 2020

A case of patient with advanced hepatocellular carcinoma - maximizing clinical benefits through timely switching away from failing regimen

31 Dec 2020

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

31 Dec 2020

Brentuximab vedotin serves as a viable option to combine with chemotherapy for advanced stage Hodgkin lymphoma

31 Dec 2020

Bruton’s tyrosine kinase inhibitors delay disease progression and extend survival in patients with relapsed/refractory mantle cell lymphoma

30 Dec 2020

Enzalutamide improves overall survival and delays metastasis in patients with nonmetastatic, castration-resistant prostate cancer: A local case review

22 Nov 2020

The use of daratumumab in multiple myeloma: Developing novel immunotherapy strategies to prolong survival

31 Aug 2020

First-line treatment with immunotherapy in metastatic squamous NSCLC

31 Aug 2020

Nasopharyngeal carcinoma management: Advances and hope

31 Aug 2020

Advanced-stage Hodgkin lymphoma in an elderly patient: A case report highlighting the efficacy of brentuximab vedotin treatment

30 Jun 2020

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

Multiple myeloma (MM) is a plasma cell malignancy with approximately 150,000 new cases globally each year.1 In 2016, approximately 270 new cases were reported in Hong Kong.1 As the second most frequent hematological disease worldwide, MM accounts for 0.9% of all new cancer cases and 1.1% of all canc

31 Dec 2020

Dr. Wong, Siu-Ming Raymond

Head of Division of Haematology,
Department of Medicine & Therapeutics,
Faculty of Medicine,
The Chinese University of Hong Kong

Brentuximab vedotin serves as a viable option to combine with chemotherapy for advanced stage Hodgkin lymphoma

The combination treatment approach of chemotherapy and radiotherapy has significantly improved the survival outcomes of patients with Hodgkin lymphoma (HL) over the past several decades.1 Whereas the conventional frontline therapies, such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), c

31 Dec 2020

Dr. Law, Man-Fai

Division of Haematology,
Department of Medicine & Therapeutics,
Prince of Wales Hospital,
Hong Kong

ESMO 2020

19 - 21 September 2020 |

Virtual

The use of daratumumab in multiple myeloma: Developing novel immunotherapy strategies to prolong survival

HEMATOLOGY ONCOLOGY

31 Aug 2020

Prof. María-Victoria Mateos

University Hospital of Salamanca-IBSAL,
Salamanca, Spain

Clinical challenges and considerations in managing HR+/HER2- advanced breast cancer in the post-CDK inhibitor setting

Demonstrating efficacy with a nearly doubled progression-free survival (PFS) rate, cyclin-dependent kinase inhibitor (CDKi) plus endocrine therapy (ET) have now become the new standard-of-care (SOC) in the first-line treatment setting of hormone receptor positive (HR+), human epidermal growth factor

31 Dec 2020

Dr. Chan, Wing-Lok Wendy

Clinical Assistant Professor,
Department of Clinical Oncology,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

IG-IMRT as a more favorable adjuvant radiation alternative for hysterectomized cervical cancer patients

Radiotherapy as adjuvant treatment after total hysterectomy has proven to be effective in lowering cancer-specific mortality rate.1 However, traditional three-dimensional conformal radiotherapy (3D-CRT) as adjuvant treatment after total hysterectomy is associated with a series of late gastrointestin

31 Dec 2020

STAR-CAP as an advanced prognostic method for localized prostate cancer

Prostate cancer was the third most common cancer among males in Hong Kong in 2018, accounting for 12.9% of total cancer cases and 5.5% of total cancer deaths.1 For decades, the anatomical extent or stage of cancer has been classified using the tumor-node-metastasis (TNM) system, but not for localize

31 Dec 2020

INFECTIOUS DISEASE ONCOLOGY

Potential new pinprick blood test for diagnosing HPV related-cancers

31 Dec 2020

First-line treatment with immunotherapy in metastatic squamous NSCLC

Immunotherapy has dramatically changed the therapeutic scenario in the treatment-naïve advanced NSCLC. While the single agent pembrolizumab has become the standard first-line therapy in patients with ≥50% PD-L1 expression on tumor cells,

31 Aug 2020

Prof. Luis Paz-Ares

Head of Medical Oncology Department,
Hospital Universitario 12 de Octubre,
Madrid, Spain